TY - JOUR
T1 - Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan
AU - Lin, Yi Jun
AU - Lin, Hsing Chieh
AU - Yang, Ying Fei
AU - Chen, Chi Yun
AU - Lu, Tien Hsuan
AU - Liao, Chung Min
N1 - Publisher Copyright:
© 2020 The Authors
PY - 2020/8
Y1 - 2020/8
N2 - Objectives: To assess the potential epidemiological impact and cost-effectiveness of shorter antibiotic regimens in high tuberculosis (TB) burden regions of Taiwan. Methods: This study combined the TB population dynamic model and cost-effectiveness analysis with local data to simulate the disease burdens, effectiveness and costs of hypothetical 4-month, 2-month and 7-day regimens compared with the standard regimen. Results: The main outcomes were the potential of shorter regimens for averted incidence, mortality and disability-adjusted life years, incremental cost-effectiveness ratio and net monetary benefit. Shorter regimens would lower incidence rates and mortality cases in a high TB burden region by an average of 19–33% and 27–41%, respectively, with the potential for cost-effectiveness or cost-saving. The 2-month and 7-day regimens would be more cost-effective than the 4-month regimen. The threshold daily drug prices for achieving cost-effectiveness and cost-saving for 4-month, 2-month and 7-day regimens were $US1, $US2 and $US70, respectively. Such cost-effectiveness would remain, even if the willingness-to-pay threshold was less than one gross domestic product per capita. Conclusions: The findings support the inclusion of shorter regimens in global guidelines and regional-scale TB control strategies, which would improve disease control, particularly in settings with high rates of incidence and poor treatment outcomes.
AB - Objectives: To assess the potential epidemiological impact and cost-effectiveness of shorter antibiotic regimens in high tuberculosis (TB) burden regions of Taiwan. Methods: This study combined the TB population dynamic model and cost-effectiveness analysis with local data to simulate the disease burdens, effectiveness and costs of hypothetical 4-month, 2-month and 7-day regimens compared with the standard regimen. Results: The main outcomes were the potential of shorter regimens for averted incidence, mortality and disability-adjusted life years, incremental cost-effectiveness ratio and net monetary benefit. Shorter regimens would lower incidence rates and mortality cases in a high TB burden region by an average of 19–33% and 27–41%, respectively, with the potential for cost-effectiveness or cost-saving. The 2-month and 7-day regimens would be more cost-effective than the 4-month regimen. The threshold daily drug prices for achieving cost-effectiveness and cost-saving for 4-month, 2-month and 7-day regimens were $US1, $US2 and $US70, respectively. Such cost-effectiveness would remain, even if the willingness-to-pay threshold was less than one gross domestic product per capita. Conclusions: The findings support the inclusion of shorter regimens in global guidelines and regional-scale TB control strategies, which would improve disease control, particularly in settings with high rates of incidence and poor treatment outcomes.
KW - Antibiotic treatment
KW - Economic evaluation
KW - Population dynamic model
KW - Shorter regimens
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85086663225&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2020.05.082
DO - 10.1016/j.ijid.2020.05.082
M3 - Article
C2 - 32474203
AN - SCOPUS:85086663225
SN - 1201-9712
VL - 97
SP - 135
EP - 142
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
ER -